Figures Guide:
Figure 1 . Duration of treatment with a combination of cabozantinib, topotecan and cyclophosphamide in patients with relapsed or refractory Ewing sarcoma and osteosarcoma (n=12).
Figure 2. Best percent change in tumor size from baseline for patients with relapsed or refractory Ewing sarcoma and osteosarcoma with measurable disease (n=5)
Figure 3. Spider plots demonstrating ctDNA levels throughout study duration for A) patients with osteosarcoma and B) patients with Ewing sarcoma